The Melbourne company Everlab founded in 2023 has built its preventive-health model around diagnostics, clinicians, wearables and AI. Its June 2026 funding round, which included Australian cricket captain Pat Cummins, was one milestone in a much broader push to turn fragmented health data into personalised preventive care.
Pat Cummins may be the best-known name on Everlab’s investor list, but the more revealing numbers sit inside the healthcare startup itself.
By June 2026, Everlab said its platform was connected with more than 1,850 health-provider locations and 180 active clinicians, worked with more than 30 wearable devices and processed over 200,000 health reports each month. The company also said it had handled more than 21 million biomarker test results across a patient base of about 20,000.
Those figures help explain what Everlab is trying to build beyond the more eye-catching idea of full-body health screening.
Founded in Melbourne in 2023 by Marc Hermann, Dr Steven Lu and Sam Kothari, Everlab is developing a preventive healthcare platform designed to bring diagnostics, medical professionals, prescriptions, health data and ongoing care into one system.
Artificial intelligence sits behind part of that process. Everlab uses it to analyse health information, identify risk markers and help develop personalised health and prevention plans, while patients can be connected with doctors or specialists when further attention is needed.
Everlab: From testing to a broader health platform
Everlab’s offering covers a wide range of diagnostics.
The company performs full-body MRI scans aimed at identifying potential problems in people who may not be showing symptoms. It also offers blood testing, genetics testing and other screening services, with its digital platform organising the information produced by those tests.
The pricing reflects the breadth of the service.
Startup Daily reported a basic health check at $299, a genetics test at $249 and an MRI body scan at $3,499, while packaged assessments ranged from $900 to $2,700. The Australian Financial Review separately reported a baseline subscription costing $300 a year, with more comprehensive screening packages involving whole-body MRI, blood tests and bone-density scans starting at $3,000.
The company has said tens of thousands of people were on its waiting lists.
Everlab also said more than 25 per cent of clients undergoing its testing had health issues detected that might otherwise have remained unnoticed. That figure is a company-reported measure rather than an independently established clinical outcome, but it is central to Everlab’s case for preventive screening.
Its testing has also been used in executive programs involving Boston Consulting Group, BHP and Bain & Company.
How the startup reached a $500 million valuation
Everlab’s June 2026 capital raise was significant, but it was not the beginning of the story.
The company had previously raised $3 million in a pre-seed round in December 2023 before launching publicly the following month. A further $15 million seed round, led by Left Lane Capital, followed in July 2025.
Then came the $65 million Series A in June 2026.
Airtree Ventures led the round at a reported valuation of $500 million. London-based Plural participated alongside existing investors Left Lane Capital and b2venture, while Cummins joined the round as an angel investor.
Everlab’s earlier investor base has also included Afterwork Ventures, Ten13, Flying Fox, Temedica and founders associated with Go1 and Aconex.
Rather than treating the Series A as an endpoint, Hermann described it at the time as capital that could give Everlab another four to five years of funding to pursue more aggressive growth.
The money was earmarked for international expansion, including the United Kingdom, as well as further investment in clinical and technology infrastructure.
Why Everlab is betting on connected health data
Hermann’s argument is that healthcare information remains too fragmented.
A scan may sit in one system, a doctor’s notes in another, wearable information somewhere else and prescriptions in yet another part of the health network. Everlab’s approach is to pull more of that information together so that a patient’s health can be viewed as a connected picture rather than a collection of isolated tests.
Its app brings together diagnostics, doctors, specialists, prescriptions and continuous AI-supported care.
The company was already working with clinics across Melbourne, Sydney, Brisbane and Perth by June 2026. Startup Daily also reported that Everlab had expanded into New Zealand, while the UK was a major focus of its next stage of growth. The Australian Financial Review reported that the company was also considering the United States or Europe as possible markets after further expansion in the UK and New Zealand.
Hermann’s experience before Everlab is relevant to that expansion ambition. He previously co-founded nutrition business Foodspring, which was acquired by Mars in 2019.
Moving beyond the ‘biohacker’ label
Preventive health and longevity services can quickly acquire an elite image, especially when full screening programs cost several thousand dollars.
Hermann acknowledged that Everlab had initially been placed in a category associated with biohackers and wealthy executives. He pushed back against the idea that the company wanted to remain a premium service available only to high-income customers.
His argument was that investment in the underlying technology could eventually make the model useful to a broader group of people.
That distinction matters for Everlab. Its longer-term opportunity depends on whether it can move from being known primarily for high-end screening into becoming infrastructure that coordinates preventive healthcare at a much larger scale.
The lower-priced health checks and subscription layer sit alongside premium diagnostic packages, giving Everlab different entry points rather than relying entirely on whole-body MRI programs.
Pat Cummins is part of a wider investor story
Cummins brings public recognition to Everlab’s shareholder roster, but the startup’s institutional backing provides a clearer indication of the scale of its ambitions.
Airtree partner John Henderson said at the time of the Series A that the firm had become increasingly convinced about Everlab while spending time with the team, pointing to its product and pace of growth as reasons for backing its international expansion.
Hermann, meanwhile, ruled out an Australian Securities Exchange listing at that stage. He said he would like to ring a listing bell one day, but made clear there was still significant work ahead.
That leaves Everlab in an interesting position.
It is only a few years removed from its 2023 founding, yet it has already moved through a $3 million pre-seed round, a $15 million seed round and a $65 million Series A. It has accumulated a reported 20,000 patients, connected its technology with 1,850 health providers and built a system processing hundreds of thousands of health reports each month.
The larger test now is not simply whether Everlab can sell more health checks.
It is whether the company can turn that growing network of diagnostic data, clinicians, wearables and AI-assisted analysis into a preventive-care model that works beyond its Australian base.
Pat Cummins may help put the startup’s name in front of a wider audience. Everlab’s future, however, will be determined by what it can do with the health infrastructure it has been assembling behind the headline.
Also Read: iPhone 18 Pro Max Pre-Order Date, 5 AM Los Angeles Time, Price, Battery Leaks
